E2F1 apoptosis counterattacked: Evil strikes back

Trends in Molecular Medicine

Volumn 19, Issue 2, 2013, Pages 89-98

  Pützer, Brigitte M ^a   Engelmann, David ^a  

^a ROSTOCK UNIVERSITY MEDICAL CENTER   (Germany)

Author keywords

Apoptosis; Chemoresistance; DNA damage; DNA repair; E2F; Post translational modifications

Indexed keywords

ANTHRACYCLINE; CELECOXIB; CYCLIN A; DNA; DOXORUBICIN; EPIRUBICIN; HISTONE DEACETYLASE 1; PROTEIN P53; SIRTUIN 1; TRANSCRIPTION FACTOR E2F1;

ACETYLATION; APOPTOSIS; BREAST CANCER; CANCER RESISTANCE; DISTANT METASTASIS; DNA DAMAGE; DNA REPAIR; GENETIC TRANSCRIPTION; HUMAN; METHYLATION; NEDDYLATION; NEOPLASM; NONHUMAN; OLIGOMERIZATION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; REVIEW; TRANSACTIVATION; TUMOR RECURRENCE;

ANIMALS; APOPTOSIS; DNA REPAIR; DRUG RESISTANCE, NEOPLASM; E2F1 TRANSCRIPTION FACTOR; HUMANS; NEOPLASMS; PROTEIN BINDING; REPRESSOR PROTEINS; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84873112147     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2012.10.009     Document Type: Review

References (79)

1. Chen H.Z., et al. Emerging roles of E2Fs in cancer: an exit from cell cycle control. Nat. Rev. Cancer 2009, 9:785-797.
2. Stanelle J., Pützer B.M. E2F1-induced apoptosis: turning killers into therapeutics. Trends Mol. Med. 2006, 12:177-185.
3. Engelmann D., Pützer B.M. Translating DNA damage into cancer cell death - A roadmap for E2F1 apoptotic signalling and opportunities for new drug combinations to overcome chemoresistance. Drug Resist. Updat. 2010, 13:119-131.
4. Kwon M.J., et al. E2F1 expression predicts outcome in Korean women who undergo surgery for breast carcinoma. Ann. Surg. Oncol. 2010, 17:564-571.
5. Lee J., et al. Impact of E2F-1 expression on clinical outcome of gastric adenocarcinoma patients with adjuvant chemoradiation therapy. Clin. Cancer Res. 2008, 14:82-88.
6. Sharma A., et al. The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression. J. Clin. Invest. 2010, 120:4478-4492.
7. Imai M.A., et al. Overexpression of E2F1 associated with LOH at RB locus and hyperphosphorylation of RB in non-small cell lung carcinoma. J. Cancer Res. Clin. Oncol. 2004, 130:320-326.
8. Han S., et al. E2F1 expression is related with the poor survival of lymph node-positive breast cancer patients treated with fluorouracil, doxorubicin and cyclophosphamide. Breast Cancer Res. Treat. 2003, 82:11-16.
9. Lee J.S., et al. Expression signature of E2F1 and its associated genes predict superficial to invasive progression of bladder tumors. J. Clin. Oncol. 2010, 28:2660-2667.
10. Alla V., et al. E2F1 in melanoma progression and metastasis. J. Natl. Cancer Inst. 2010, 102:127-133.
11. Berkovich E., Ginsberg D. ATM is a target for positive regulation by E2F-1. Oncogene 2003, 22:161-167.
12. Real S., et al. Study of the in vivo phosphorylation of E2F1 on Ser403. Biochim. Biophys. Acta 2010, 1803:912-918.
13. Ianari A., et al. Specific role for p300/CREB-binding protein-associated factor activity in E2F1 stabilization in response to DNA damage. J. Biol. Chem. 2004, 279:30830-30835.
14. Galbiati L., et al. Regulation of E2F-1 after DNA damage by p300-mediated acetylation and ubiquitination. Cell Cycle 2005, 4:930-939.
15. Budhavarapu V.N., et al. Regulation of E2F1 by APC/C Cdh1 via K11 linkage-specific ubiquitin chain formation. Cell Cycle 2012, 11:2030-2038.
16. Millour J., et al. ATM and p53 regulate FOXM1 expression via E2F in breast cancer epirubicin treatment and resistance. Mol. Cancer Ther. 2011, 10:1046-1058.
17. de Olano N., et al. The p38 MAPK-MK2 axis regulates E2F1 and FOXM1 expression in epirubicin treatment. Mol. Cancer Res. 2012, 10:1189-1202.
18. Hirano G., et al. Enhanced expression of PCAF endows apoptosis resistance in cisplatin-resistant cells. Mol. Cancer Res. 2010, 8:864-872.
19. Taubert S., et al. E2F-dependent histone acetylation and recruitment of the Tip60 acetyltransferase complex to chromatin in late G1. Mol. Cell. Biol. 2004, 24:4546-4556.
20. Van Den Broeck A., et al. Activation of a Tip60/E2F1/ERCC1 network in human lung adenocarcinoma cells exposed to cisplatin. Carcinogenesis 2012, 33:320-325.
21. Bohanes P., et al. A review of excision repair cross-complementation group 1 in colorectal cancer. Clin. Colorectal Cancer 2011, 10:157-164.
22. Miyamoto N., et al. Tip60 is regulated by circadian transcription factor clock and is involved in cisplatin resistance. J. Biol. Chem. 2008, 283:18218-18226.
23. Pediconi N., et al. hSirT1-dependent regulation of the PCAF-E2F1-p73 apoptotic pathway in response to DNA damage. Mol. Cell. Biol. 2009, 29:1989-1998.
24. Olmos Y., et al. Interplay between SIRT proteins and tumour suppressor transcription factors in chemotherapeutic resistance of cancer. Drug Resist. Updat. 2011, 14:35-44.
25. Kontaki H., Talianidis I. Lysine methylation regulates E2F1-induced cell death. Mol. Cell 2010, 39:152-160.
26. Xie Q., et al. Methylation-mediated regulation of E2F1 in DNA damage-induced cell death. J. Recept. Signal Transduct. Res. 2011, 31:139-146.
27. Loftus S.J., et al. NEDDylation regulates E2F-1-dependent transcription. EMBO Rep. 2012, 13:811-818.
28. McDonald O.G., et al. Genome-scale epigenetic reprogramming during epithelial-to-mesenchymal transition. Nat. Struct. Mol. Biol. 2011, 18:867-874.
29. Cho E.C., et al. Arginine methylation controls growth regulation by E2F-1. EMBO J. 2012, 31:1785-1797.
30. Wang C., et al. Regulation of E2F1 function by the nuclear corepressor KAP1. J. Biol. Chem. 2007, 282:29902-29909.
31. Hallstrom T.C., Nevins J.R. Specificity in the activation and control of transcription factor E2F-dependent apoptosis. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:10848-10853.
32. Hu C., et al. Roles of Kruppel-associated box (KRAB)-associated co-repressor KAP1 Ser-473 phosphorylation in DNA damage response. J. Biol. Chem. 2012, 287:18937-18952.
33. Iyengar S., Farnham P.J. KAP1 protein: an enigmatic master regulator of the genome. J. Biol. Chem. 2011, 286:26267-26276.
34. Novy M., et al. EAPP, a novel E2F binding protein that modulates E2F-dependent transcription. Mol. Biol. Cell 2005, 16:2181-2190.
35. Andorfer P., Rotheneder H. EAPP: gatekeeper at the crossroad of apoptosis and p21-mediated cell-cycle arrest. Oncogene 2011, 30:2679-2690.
36. Milton A., et al. A functionally distinct member of the DP family of E2F subunits. Oncogene 2006, 25:3212-3218.
37. Ingram L., et al. E2F-1 regulation by an unusual DNA damage-responsive DP partner subunit. Cell Death Differ. 2011, 18:122-132.
38. Tian C., et al. TFDP3 inhibits E2F1-induced, p53-mediated apoptosis. Biochem. Biophys. Res. Commun. 2007, 361:20-25.
39. Revenko A.S., et al. Chromatin loading of E2F-MLL complex by cancer-associated coregulator ANCCA via reading a specific histone mark. Mol. Cell. Biol. 2010, 30:5260-5272.
40. Ciro M., et al. ATAD2 is a novel cofactor for MYC, overexpressed and amplified in aggressive tumors. Cancer Res. 2009, 69:8491-8498.
41. Kalashnikova E.V., et al. ANCCA/ATAD2 overexpression identifies breast cancer patients with poor prognosis, acting to drive proliferation and survival of triple-negative cells through control of B-Myb and EZH2. Cancer Res. 2010, 70:9402-9412.
42. Caron C., et al. Functional characterization of ATAD2 as a new cancer/testis factor and a predictor of poor prognosis in breast and lung cancers. Oncogene 2010, 29:5171-5181.
43. Wu Z.L., et al. Polycomb protein EZH2 regulates E2F1-dependent apoptosis through epigenetically modulating Bim expression. Cell Death Differ. 2010, 17:801-810.
44. Hallstrom T.C., et al. An E2F1-dependent gene expression program that determines the balance between proliferation and cell death. Cancer Cell 2008, 13:11-22.
45. Hallstrom T.C., Nevins J.R. Jab1 is a specificity factor for E2F1-induced apoptosis. Genes Dev. 2006, 20:613-623.
46. Lu H., et al. Jab1/CSN5 mediates E2F dependent expression of mitotic and apoptotic but not DNA replication targets. Cell Cycle 2011, 10:3317-3326.
47. Liu K., et al. Regulation of E2F1 by BRCT domain-containing protein TopBP1. Mol. Cell. Biol. 2003, 23:3287-3304.
48. Liu K., et al. TopBP1 recruits Brg1/Brm to repress E2F1-induced apoptosis, a novel pRb-independent and E2F1-specific control for cell survival. Genes Dev. 2004, 18:673-686.
49. Liu K., et al. Regulation of TopBP1 oligomerization by Akt/PKB for cell survival. EMBO J. 2006, 25:4795-4807.
50. Chaussepied M., Ginsberg D. Transcriptional regulation of AKT activation by E2F. Mol. Cell 2004, 16:831-837.
51. Ginsberg D. EGFR signaling inhibits E2F1-induced apoptosis in vivo: implications for cancer therapy. Sci. STKE 2007, 2007:pe4.
52. Wikonkal N.M., et al. Inactivating E2f1 reverts apoptosis resistance and cancer sensitivity in Trp53-deficient mice. Nat. Cell Biol. 2003, 5:655-660.
53. Guo R., et al. E2F1 localizes to sites of UV-induced DNA damage to enhance nucleotide excision repair. J. Biol. Chem. 2010, 285:19308-19315.
54. Guo R., et al. GCN5 and E2F1 stimulate nucleotide excision repair by promoting H3K9 acetylation at sites of damage. Nucleic Acids Res. 2011, 39:1390-1397.
55. Chen J., et al. E2F1 promotes the recruitment of DNA repair factors to sites of DNA double-strand breaks. Cell Cycle 2011, 10:1287-1294.
56. Jin R., et al. E2F1 is involved in DNA single-strand break repair through cell-cycle-dependent upregulation of XRCC1 expression. DNA Repair (Amst.) 2011, 10:926-933.
57. Yang S.Z., et al. MCPH1/BRIT1 cooperates with E2F1 in the activation of checkpoint, DNA repair and apoptosis. EMBO Rep. 2008, 9:907-915.
58. Hayes S., et al. DDB, a putative DNA repair protein, can function as a transcriptional partner of E2F1. Mol. Cell. Biol. 1998, 18:240-249.
59. Carcagno A.L., et al. E2F1 induces p19INK4d, a protein involved in the DNA damage response, following UV irradiation. Mol. Cell. Biochem. 2012, 366:123-129.
60. Polager S., Ginsberg D. p53 and E2f: partners in life and death. Nat. Rev. Cancer 2009, 9:738-748.
61. Nip J., et al. E2F-1 induces the stabilization of p53 but blocks p53-mediated transactivation. Oncogene 2001, 20:910-920.
62. Yoshihara Y., et al. Inhibitory role of E2F-1 in the regulation of tumor suppressor p53 during DNA damage response. Biochem. Biophys. Res. Commun. 2012, 421:57-63.
63. Bug M., Dobbelstein M. Anthracyclines induce the accumulation of mutant p53 through E2F1-dependent and -independent mechanisms. Oncogene 2011, 30:3612-3624.
64. Buhlmann S., Pützer B.M. DNp73 a matter of cancer: mechanisms and clinical implications. Biochim. Biophys. Acta 2008, 1785:207-216.
65. Stiewe T., et al. Transactivation-deficient Delta TA-p73 inhibits p53 by direct competition for DNA binding: implications for tumorigenesis. J. Biol. Chem. 2002, 277:14177-14185.
66. Emmrich S., et al. Antisense gapmers selectively suppress individual oncogenic p73 splice isoforms and inhibit tumor growth in vivo. Mol. Cancer 2009, 8:61.
67. Lau L.M., et al. Cyclooxygenase inhibitors differentially modulate p73 isoforms in neuroblastoma. Oncogene 2009, 28:2024-2033.
68. Alla V., et al. E2F1 confers anticancer drug resistance by targeting ABC transporter family members and Bcl-2 via the p73/DNp73-miR-205 circuitry. Cell Cycle 2012, 11:3067-3078.
69. Dar A.A., et al. miRNA-205 suppresses melanoma cell proliferation and induces senescence via regulation of E2F1 protein. J. Biol. Chem. 2011, 286:16606-16614.
70. Engelmann D., et al. Functional interplay between E2F1 and chemotherapeutic drugs defines immediate E2F1 target genes crucial for cancer cell death. Cell. Mol. Life Sci. 2010, 67:931-948.
71. Engelmann D., Pützer B.M. The dark side of E2F1: in transit beyond apoptosis. Cancer Res. 2012, 72:571-575.
72. Johnson J.L., et al. Regulation of matrix metalloproteinase genes by E2F transcription factors: Rb-Raf-1 interaction as a novel target for metastatic disease. Cancer Res. 2012, 72:516-526.
73. Carnevale J., et al. DNA damage signals through differentially modified E2F1 molecules to induce apoptosis. Mol. Cell. Biol. 2012, 32:900-912.
74. Ianari A., et al. Proapoptotic function of the retinoblastoma tumor suppressor protein. Cancer Cell 2009, 15:184-194.
75. Andersen J.B., et al. An integrated genomic and epigenomic approach predicts therapeutic response to zebularine in human liver cancer. Sci. Transl. Med. 2010, 2:54ra77.
76. Huang L., et al. An integrated bioinformatics approach identifies elevated cyclin E2 expression and E2F activity as distinct features of tamoxifen resistant breast tumors. PLoS ONE 2011, 6:e22274.
77. Kinkade R., et al. A small molecule disruptor of Rb/Raf-1 interaction inhibits cell proliferation, angiogenesis, and growth of human tumor xenografts in nude mice. Cancer Res. 2008, 68:3810-3818.
78. Saha A., et al. E2F1 mediated apoptosis induced by the DNA damage response is blocked by EBV nuclear antigen 3C in lymphoblastoid cells. PLoS Pathog. 2012, 8:e1002573.
79. Young L.S., Rickinson A.B. Epstein-Barr virus: 40 years on. Nat. Rev. Cancer 2004, 4:757-768.